Cargando…

Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis

BACKGROUND: Formoterol and salmeterol are two long-acting β2-agonists given by inhalation, with bronchodilating effects lasting for at least 12 h after a single administration. Formoterol has a faster onset of action compared with salmeterol. The aim of this study was to perform a systematic review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velayati, Ashraf, Hosseini, Seyed Alireza, Sari, Ali Akbari, Mohtasham, Farideh, Ghanei, Mostafa, Yaghoubi, Mohsen, Majdzadeh, Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590204/ https://www.ncbi.nlm.nih.gov/pubmed/26487878

Ejemplares similares

The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test
por: Mousavinezhad, Maryam, et al.
Publicado: (2016)

Formoterol is more effective than salmeterol in suppressing neutrophil reactivity
por: Tintinger, Gregory R., et al.
Publicado: (2015)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2010)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

188 Efficacy Comparison of Mometasone Furoate/Formoterol Versus Fluticasone Propionate/Salmeterol Combination Therapies in Subjects With Persistent Asthma: Noninferiority and Onset-of-Action Findings
por: Bernstein, David, et al.
Publicado: (2012)

Investigation of the efficacy of generic and brand-name salmeterol/fluticasone combination in the management of asthma: a randomized comparative trial
por: Panahi, Yunes, et al.
Publicado: (2018)

Impact assessment of Iran’s health technology assessment programme
por: Yazdizadeh, Bahareh, et al.
Publicado: (2018)

Correction to: Impact assessment of Iran’s health technology assessment programme
por: Yazdizadeh, Bahareh, et al.
Publicado: (2018)

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
por: Bodzenta-Lukaszyk, Anna, et al.
Publicado: (2011)

Evaluation of a Therapeutic Interchange from Fluticasone/Salmeterol to Mometasone/Formoterol in Patients with Chronic Obstructive Pulmonary Disease
por: Yip, Elaine, et al.
Publicado: (2016)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study)
por: Shimizu, Yasuo, et al.
Publicado: (2020)

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
por: Price, David, et al.
Publicado: (2013)

Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
por: Price, David B, et al.
Publicado: (2007)

Adverse effects of salmeterol in asthma: a neuronal perspective
por: Lommatzsch, M, et al.
Publicado: (2009)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
por: Perrone, Valentina, et al.
Publicado: (2016)

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
por: KAGOHASHI, KATSUNORI, et al.
Publicado: (2014)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]
Publicado: (2017)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
por: Stanford, Richard H, et al.
Publicado: (2012)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
por: Pitrez, Paulo Marcio, et al.
Publicado: (2023)

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
por: Beier, Jutta, et al.
Publicado: (2012)

Health technology assessment in Iran: Barriers and solutions
por: Mohtasham, Farideh, et al.
Publicado: (2016)

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006)

Long-Term Safety of Mometasone Furoate/Formoterol Combination for Treatment of Patients with Persistent Asthma
por: Maspero, Jorge F, et al.
Publicado: (2010)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
por: Teply, Robyn, et al.
Publicado: (2010)

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
por: Bullone, Michela, et al.
Publicado: (2017)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016)

Systematic review and policy dialogue to determine challenges in evidence-informed health policy-making: findings of the SASHA study
por: Yazdizadeh, Bahareh, et al.
Publicado: (2021)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
por: Dalby, Chris, et al.
Publicado: (2009)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]
Publicado: (2021)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
por: Sadatsafavi, Mohsen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_erioe9i8kufbdmcqa9kmuufqn2